CombiGene AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COMBI.ST research report →
Companywww.combigene.com
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies.
- CEO
- Peter Ekolind
- IPO
- 2015
- Employees
- 9
- HQ
- Lidingö, SE
Price Chart
Valuation
- Market Cap
- $48.91M
- P/E
- -1.72
- P/S
- 26.42
- P/B
- 0.82
- EV/EBITDA
- 0.95
- Div Yield
- 86.96%
Profitability
- Gross Margin
- -205.22%
- Op Margin
- -1657.37%
- Net Margin
- -1536.89%
- ROE
- -43.64%
- ROIC
- -51.69%
Growth & Income
- Revenue
- $326.00K · -94.12%
- Net Income
- $-44,878,000 · -25.83%
- EPS
- $-2.27 · -26.11%
- Op Income
- $-47,218,000
- FCF YoY
- 2.34%
Performance & Tape
- 52W High
- $3.18
- 52W Low
- $1.27
- 50D MA
- $2.48
- 200D MA
- $2.46
- Beta
- 1.22
- Avg Volume
- 24.61K
Get TickerSpark's AI analysis on COMBI.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our COMBI.ST Coverage
We haven't published any research on COMBI.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate COMBI.ST Report →